{"id":11478,"date":"2023-01-30T10:15:56","date_gmt":"2023-01-30T09:15:56","guid":{"rendered":"https:\/\/ggba.swiss\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/"},"modified":"2023-07-04T13:44:12","modified_gmt":"2023-07-04T11:44:12","slug":"alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/","title":{"rendered":"Alithea Genomics et le CHUV vont aider \u00e0 rendre les traitements d\u2019immunoth\u00e9rapie plus cibl\u00e9s"},"content":{"rendered":"\n<p><a href=\"https:\/\/alitheagenomics.com\/\" target=\"_blank\" rel=\"noopener\">Alithea Genomics<\/a> est sp\u00e9cialis\u00e9e dans le s\u00e9quen\u00e7age de l&rsquo;ARN et l&rsquo;analyse transcriptomique. Sa technologie brevet\u00e9e, Bulk RNA Barcoding and sequencing (BRB-seq), permet de pr\u00e9parer des centaines d&rsquo;\u00e9chantillons d&rsquo;ARN pour le s\u00e9quen\u00e7age dans un seul tube. Le s\u00e9quen\u00e7age de l&rsquo;ARN utilise le NGS pour \u00e9valuer la quantit\u00e9 et la s\u00e9quence de l&rsquo;ARN dans un \u00e9chantillon biologique. Les donn\u00e9es obtenues montrent quels g\u00e8nes de l&rsquo;ADN sont activ\u00e9s ou d\u00e9sactiv\u00e9s, et \u00e0 quel degr\u00e9, par exemple dans une cellule malade ou en r\u00e9ponse \u00e0 un m\u00e9dicament. Depuis le lancement des kits BRB-seq sur le march\u00e9, Alithea a vendu plus de 500 kits en Suisse, en Europe, au Royaume-Uni et aux \u00c9tats-Unis.<\/p>\n<p>La technologie d&rsquo;Alithea sera essentielle dans le projet r\u00e9cemment r\u00e9v\u00e9l\u00e9, financ\u00e9 par Eurostars et dirig\u00e9 par le consortium MAINLINE. Alithea s&rsquo;est associ\u00e9e \u00e0 <a href=\"https:\/\/pamgene.com\/\" target=\"_blank\" rel=\"noopener\">PamGene International<\/a> et au Centre Hospitalier Universitaire de Lausanne (<a href=\"https:\/\/www.chuv.ch\/fr\/chuv-home\/\" target=\"_blank\" rel=\"noopener\">CHUV<\/a>) pour combiner leur expertise en recherche clinique, en transcriptomique et en profilage kinomique et cr\u00e9er un nouveau profil de biomarqueur multi-omique qui surpasse les m\u00e9thodes actuelles de biomarqueur unique.<\/p>\n<p>Auparavant, PamGene a d\u00e9velopp\u00e9 deux tests CE-IVD pour le guidage du traitement par ICI, les tests IOpener\u00ae pour le guidage du traitement par ICI des patients atteints de NSCLC et de m\u00e9lanome avanc\u00e9. Dans le cadre du consortium MAINLINE, PamGene vise \u00e0 \u00e9tendre ces \u00e9tudes afin de cr\u00e9er un profil kinomique pr\u00e9dictif complet pour le traitement par ICI.<\/p>\n<h4>Une perc\u00e9e dans le d\u00e9veloppement de tests de pr\u00e9diction de l&rsquo;ICI pour l&rsquo;ensemble des cancers<\/h4>\n<p>Tous deux bas\u00e9s dans le canton de Vaud, le CHUV et Alithea Genomics vont cr\u00e9er un panel de biomarqueurs transcriptomiques en utilisant leur plateforme BRB-seq efficace et rentable. Le CHUV fournira des \u00e9chantillons de sang provenant de patients canc\u00e9reux \u00e9ligibles \u00e0 l&rsquo;ICI afin d&rsquo;\u00e9tablir un ensemble de donn\u00e9es complet pour l&rsquo;entra\u00eenement et la validation du mod\u00e8le de pr\u00e9diction. En int\u00e9grant les profils kinomiques et transcriptomiques individuels aux donn\u00e9es cliniques, ils formeront un nouveau mod\u00e8le multi-omique et valideront cliniquement sa force pr\u00e9dictive dans ce projet.<\/p>\n<p>Riccardo Dainese, CEO d&rsquo;Alithea Genomics, conclut : \u00ab&nbsp;L&rsquo;approbation par les agences de financement suisses et n\u00e9erlandaises de notre projet Eurostars t\u00e9moigne de la qualit\u00e9 de la science et des technologies de pointe que nous utiliserons au sein de notre consortium pour mettre au point le premier test de pr\u00e9diction de la r\u00e9ponse aux ICI, agnostique aux traitements anticanc\u00e9reux.&nbsp;\u00bb<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Le consortium n\u00e9erlando-suisse MAINLINE, compos\u00e9 de PamGene International B.V., d&rsquo;Alithea Genomics et du CHUV, a re\u00e7u une subvention Eurostars de EUR 1 million pour cr\u00e9er un test sanguin complet de d\u00e9pistage du cancer permettant de pr\u00e9voir l&rsquo;efficacit\u00e9 et les effets n\u00e9fastes des inhibiteurs de points de contr\u00f4le immunitaire (ICI).<\/p>\n","protected":false},"author":3,"featured_media":11479,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1022,1032,1041,1065,1068],"class_list":["post-11478","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr","tag-diagnostic-fr","tag-financing-fr","tag-oncology-fr","tag-personalized-medicine-fr"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alithea Genomics et le CHUV vont aider \u00e0 rendre les traitements d\u2019immunoth\u00e9rapie plus cibl\u00e9s - Greater Geneva Bern area<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alithea Genomics et le CHUV vont aider \u00e0 rendre les traitements d\u2019immunoth\u00e9rapie plus cibl\u00e9s - Greater Geneva Bern area\" \/>\n<meta property=\"og:description\" content=\"Le consortium n\u00e9erlando-suisse MAINLINE, compos\u00e9 de PamGene International B.V., d&#039;Alithea Genomics et du CHUV, a re\u00e7u une subvention Eurostars de EUR 1 million pour cr\u00e9er un test sanguin complet de d\u00e9pistage du cancer permettant de pr\u00e9voir l&#039;efficacit\u00e9 et les effets n\u00e9fastes des inhibiteurs de points de contr\u00f4le immunitaire (ICI).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-30T09:15:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-04T11:44:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/Alithea-Genomics-Blood-test-630x380-1-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"630\" \/>\n\t<meta property=\"og:image:height\" content=\"380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"mathieu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"mathieu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/\"},\"author\":{\"name\":\"mathieu\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"headline\":\"Alithea Genomics et le CHUV vont aider \u00e0 rendre les traitements d\u2019immunoth\u00e9rapie plus cibl\u00e9s\",\"datePublished\":\"2023-01-30T09:15:56+00:00\",\"dateModified\":\"2023-07-04T11:44:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/\"},\"wordCount\":459,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Alithea-Genomics-Blood-test-630x380-1-2.jpg\",\"keywords\":[\"Biotech\",\"Diagnostic\",\"Financing\",\"Oncology\",\"Personalized Medicine\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/\",\"name\":\"Alithea Genomics et le CHUV vont aider \u00e0 rendre les traitements d\u2019immunoth\u00e9rapie plus cibl\u00e9s - Greater Geneva Bern area\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Alithea-Genomics-Blood-test-630x380-1-2.jpg\",\"datePublished\":\"2023-01-30T09:15:56+00:00\",\"dateModified\":\"2023-07-04T11:44:12+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Alithea-Genomics-Blood-test-630x380-1-2.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Alithea-Genomics-Blood-test-630x380-1-2.jpg\",\"width\":630,\"height\":380},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alithea Genomics et le CHUV vont aider \u00e0 rendre les traitements d\u2019immunoth\u00e9rapie plus cibl\u00e9s\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\",\"name\":\"mathieu\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/mathieu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alithea Genomics et le CHUV vont aider \u00e0 rendre les traitements d\u2019immunoth\u00e9rapie plus cibl\u00e9s - Greater Geneva Bern area","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/","og_locale":"fr_FR","og_type":"article","og_title":"Alithea Genomics et le CHUV vont aider \u00e0 rendre les traitements d\u2019immunoth\u00e9rapie plus cibl\u00e9s - Greater Geneva Bern area","og_description":"Le consortium n\u00e9erlando-suisse MAINLINE, compos\u00e9 de PamGene International B.V., d'Alithea Genomics et du CHUV, a re\u00e7u une subvention Eurostars de EUR 1 million pour cr\u00e9er un test sanguin complet de d\u00e9pistage du cancer permettant de pr\u00e9voir l'efficacit\u00e9 et les effets n\u00e9fastes des inhibiteurs de points de contr\u00f4le immunitaire (ICI).","og_url":"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2023-01-30T09:15:56+00:00","article_modified_time":"2023-07-04T11:44:12+00:00","og_image":[{"width":630,"height":380,"url":"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/Alithea-Genomics-Blood-test-630x380-1-2.jpg","type":"image\/jpeg"}],"author":"mathieu","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"mathieu","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/"},"author":{"name":"mathieu","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"headline":"Alithea Genomics et le CHUV vont aider \u00e0 rendre les traitements d\u2019immunoth\u00e9rapie plus cibl\u00e9s","datePublished":"2023-01-30T09:15:56+00:00","dateModified":"2023-07-04T11:44:12+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/"},"wordCount":459,"image":{"@id":"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Alithea-Genomics-Blood-test-630x380-1-2.jpg","keywords":["Biotech","Diagnostic","Financing","Oncology","Personalized Medicine"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/","url":"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/","name":"Alithea Genomics et le CHUV vont aider \u00e0 rendre les traitements d\u2019immunoth\u00e9rapie plus cibl\u00e9s - Greater Geneva Bern area","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Alithea-Genomics-Blood-test-630x380-1-2.jpg","datePublished":"2023-01-30T09:15:56+00:00","dateModified":"2023-07-04T11:44:12+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Alithea-Genomics-Blood-test-630x380-1-2.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Alithea-Genomics-Blood-test-630x380-1-2.jpg","width":630,"height":380},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/alithea-genomics-et-le-chuv-vont-aider-a-rendre-les-traitements-dimmunotherapie-plus-cibles\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Alithea Genomics et le CHUV vont aider \u00e0 rendre les traitements d\u2019immunoth\u00e9rapie plus cibl\u00e9s"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab","name":"mathieu","url":"https:\/\/ggba.swiss\/fr\/author\/mathieu\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/11478","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=11478"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/11478\/revisions"}],"predecessor-version":[{"id":18314,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/11478\/revisions\/18314"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/11479"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=11478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=11478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=11478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}